HypertensionRandomised controlled trial
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension
- Randomised controlled trial
- phase 3
- multinational
- double-blind
- placebo-controlled
Authors' conclusion
Among patients with uncontrolled or resistant hypertension, the addition of baxdrostat to background therapy resulted in a significantly lower seated systolic blood pressure at 12 weeks than placebo.
Study context
- Population
- Uncontrolled (2 drugs) or resistant (≥3 drugs, incl. a diuretic) hypertension, seated SBP 140 to <170 mm Hg794 received treatment
- Participants
- 796 participants
- Comparison
- Baxdrostat 1 mg or 2 mg vs placebo, added to background therapy
- 1-mg baxdrostatn = 264
- 2-mg baxdrostatn = 266
- Placebon = 264reference
- Primary endpoint
- Change in seated SBP from baseline
- Follow-up
- Week 12
Primary result
As reported in the abstract
Change in seated SBP (least-squares mean) · 12 weeks
1-mg baxdrostat
−14.5
least-squares mean change · 95% CI −16.5–-12.5 · mm Hg
2-mg baxdrostat
−15.7
least-squares mean change · 95% CI −17.6–-13.7 · mm Hg
Placebo
−5.8
least-squares mean change · 95% CI −7.9–-3.8 · mm Hg
Each group vs placeboPlacebo-corrected difference, mm Hg (95% CI)P value
1-mg baxdrostat
−8.7(−11.5 to −5.8)
P < 0.0012-mg baxdrostat
−9.8(−12.6 to −7.0)
P < 0.001Safety
Potassium >6.0 mmol/L
Original publication
Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. Published 30 August 2025. doi:10.1056/nejmoa2507109
Summarised from the published abstract; every number is checked against it